Clinical-to-Commercial Supply Transition: How to Hand Off Without Dropping Anything

For years, the clinical supply team has been the only supply chain the product has ever known. Then approval approaches, and almost everything changes at once: the packaging, the systems, the distribution network, the regulations, the demand signal, and often the people. The clinical-to-commercial transition is one of the most consequential handoffs in a product's life — and one of the least rehearsed, because many biotechs only do it once.

Get it right, and patients get product on launch day while trial participants never notice a thing. Get it wrong, and you can have an approved drug with nothing saleable on the shelf — or trial patients whose supply slips through the gap between two organisations.

What actually changes between clinical and commercial supply?

Nearly every layer of the supply chain:

• Packaging & labels — Clinical supply: Blinded or open-label kits, clinical labels, often booklets; Commercial supply: Approved commercial packs and labeling per market
• Demand signal — Clinical supply: Protocol, enrollment, IRT; Commercial supply: Market forecast, orders, wholesaler behavior
• Systems — Clinical supply: IRT/RTSM, clinical inventory tools; Commercial supply: ERP, order management, serialization systems
• Distribution — Clinical supply: Clinical depots to investigator sites; Commercial supply: 3PLs, wholesalers, specialty pharmacies, hospitals
• Manufacturing basis — Clinical supply: GMP for IMPs, evolving process; Commercial supply: Validated commercial process, approved specifications
• Traceability — Clinical supply: Kit-level accountability; Commercial supply: Serialization and traceability (e.g., DSCSA in the US, FMD in the EU)
• Ownership — Clinical supply: Clinical supply / clinical operations; Commercial supply: Commercial supply chain / technical operations

Each row is a workstream. Together they're a program.

When should launch supply planning start?

Earlier than almost everyone expects. A useful rule of thumb is to work backward from the anticipated approval date: commercial packaging components, serialization readiness, and launch inventory all carry long lead times, and launch inventory is often built before approval, at risk, so that product can ship as soon as it's authorised.

Two to three years before anticipated launch is a sensible point to have a named owner and a transition plan — especially for a first-launch biotech that doesn't yet have commercial supply infrastructure at all.

What are the critical workstreams?

1. Manufacturing readiness. The commercial process must be validated, the approved specifications set, and commercial-scale capacity secured. Supply continuity decisions — single source or dual source, where to manufacture — are strategic, and shaped increasingly by the reshoring and tariffs landscape.

2. Packaging, labeling, and artwork. Commercial artwork depends on approved labeling, which may not be final until very late. Plan artwork workflows that can absorb final label changes without derailing packaging.

3. Serialization and traceability. Commercial packs need unique identifiers and systems that exchange traceability data with trading partners. In the US that means DSCSA; in the EU, the Falsified Medicines Directive. This is typically the workstream with the least clinical-side precedent.

4. Distribution model. Decide the commercial channel — wholesaler, specialty pharmacy, specialty distributor, direct to hospital — and qualify the partners. Distribution obligations shift from clinical GDP practices to full commercial GDP, a distinction covered in our GMP vs GDP post.

5. Launch forecast and inventory build. Commercial demand is driven by market access and uptake, not a protocol. Early forecasts are highly uncertain, so launch inventory strategy should balance the cost of at-risk build against the cost of a launch stock-out.

6. Systems and data. ERP, order management, and serialization systems need to be in place and tested, with master data for every SKU and market.

What happens to patients still on study?

This is the most frequently under-planned part of the transition. At approval, many patients are still receiving product: in the pivotal study's follow-up, in an open-label extension, in rollover protocols, or in early access programs. Their supply can't pause while the organisation reorganises.

Decide early:

• How long clinical supply will continue alongside commercial supply, and from which inventory.
• Whether clinical patients can transition to commercial product — and in which countries, since approval and reimbursement arrive at different times in different markets.
• How [post-trial access](/expanded-access-post-trial-access-supply) will be provided for participants in countries where commercial product won't be available.
• Who owns these patients' supply during the overlap — clinical supply, commercial supply, or a dedicated team.

What does a smooth transition look like organisationally?

The best transitions treat it as a formal program with a single accountable owner, a joint clinical–commercial governance forum, and an explicit handover date for each workstream. The worst treat it as something the commercial team will "pick up" at approval.

For many small and mid-size biotechs, this is exactly the moment when a build vs buy decision about supply capability becomes urgent: launch requires skills the organisation hasn't needed before, and needs them before the permanent team exists.